评估在急性髓系白血病病例中使用维奈克拉、高三尖酯碱和地西他滨治疗后的延长生存率和患者健康-病例对照研究  

Assessing the Extended Survival Rate and Patient Wellness Following Treatment with Veneckra,Hyperacute Alkali,and Decitabine in Acute Myeloid Leukemia Cases-A Case-control Study

作　　者：裴晓杭 孔黛[1] 张丽娜 张萍 连成 张文荟[1] PEI Xiao-hang;KONG Dai;ZHANG Li-na;ZHANG Ping;LIAN Cheng;ZHANG Wen-hui(Department of Hematology,Henan Provincial People's Hospital,Zhengzhou 450003,Henan Province,China)

机构地区：[1]河南省人民医院血液科,河南郑州450003

出　　处：《罕少疾病杂志》2024年第4期104-106,共3页Journal of Rare and Uncommon Diseases

基　　金：2023年度河南省医学科技攻关计划联合共建项目(LHGJ20230016)。

摘　　要：目的急性髓系白血病(AML)是一个重要的治疗挑战,迫切需要延长生存期和提高患者健康状况的治疗方法。本研究旨在评估联合使用维奈克拉、高三尖酯碱和地西他滨治疗对AML患者生存率和健康状况的影响。方法在这项病例对照研究中,将50名AML患者分为两组:一组接受维奈克拉、高三尖酯碱和地西他滨治疗的研究组,以及一组接受标准护理的对照组。比较了两组之间的常规血液检测指标、临床疗效、不良反应和统计分析。结果研究组的临床应答率(88%)高于对照组(80%)。在所有类别中,研究组的不良反应较低,包括脱发、胃肠道反应、肝功能损害和肺部感染。统计分析结果显示,两组之间的常规血液检测指标和临床疗效的差异在统计学上并不显著,但在临床上具有相关性。结论研究结果表明,联合使用维奈克拉、高三尖酯碱和地西他滨的治疗方案可能能够提高AML患者的临床应答率,并减少不良反应。这些结果需要在更大规模、更全面的研究中进一步验证,以确立该治疗方法在AML管理中的作用。Objective Background Acute myeloid leukemia(AML)presents a significant therapeutic challenge,with a pressing need for treatments that extend survival and enhance patient well-being.This study was conducted to assess the impact of a treatment regimen combining Veneckra,Hyperacute Alkali,and Decitabine on the survival rate and wellness of AML patients.Methods In this case-control study,50 AML patients were divided into two groups:a study group treated with a regimen of Veneckra,Hyperacute Alkali,and Decitabine,and a control group treated with standard care.Routine blood test indices,clinical efficacy,adverse reactions,and statistical analysis were compared between the two groups.Results The study group demonstrated a higher clinical response rate(88%)compared to the control group(80%).Adverse reactions were lower in the study group across all categories:alopecia,gastrointestinal reactions,liver function damage,and lung infections.The results of the statistical analysis showed that the differences in routine blood test indices and clinical efficacy between the two groups were not statistically significant but clinically relevant.Conclusion The findings suggested that the treatment regimen combining Veneckra,Hyperacute Alkali,and Decitabine could potentially enhance the clinical response rate and reduce adverse reactions in AML patients.These results warrant further investigation in larger,more comprehensive studies to conclusively establish the role of this treatment approach in AML management.

关 键 词：急性髓系白血病 维奈克拉 高三尖酯碱 地西他滨 生存率 患者健康状况 

分 类 号：R733.7[医药卫生—肿瘤]